Trusted Resources: Education
Scientific literature and patient education texts
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type A
source: Molecular genetics and metabolism
year: 2021
authors: Wijburg FA,Heap F,Rust S,de Ruijter J,Tump E,Marchal JP,Nestrasil I,Shapiro E,Jones SA,Alexanderian D
summary/abstract:Currently, there is no effective therapy for mucopolysaccharidosis IIIA (MPS IIIA). Intravenously-administered enzyme replacement therapies, while effective in other forms of MPS without neurological involvement, have not been successful in patients with MPS IIIA, as they are unable to cross the blood-brain barrier to improve neurological symptoms. We evaluated the long-term safety, tolerability, and clinical outcomes of recombinant human heparan-N-sulfatase (rhHNS) administered intrathecally (IT) in children with MPS IIIA in a phase 1/2 extension study.
organization: Amsterdam UMC, University of Amsterdam, Pediatric Metabolic Diseases, Emma Children's Hospital and Amsterdam Lysosome Center "Sphinx", Amsterdam, the Netherlands. Electronic address: f.a.wijburg@amc.uva.nl.DOI: 10.1016/j.ymgme.2021.09.003
read more
Related Content
-
Beverly L. Davidson, PhDBeverly L. Davidson, PhD, is Director of...
-
Cure Sanfilippo Foundation – InstagramCure Sanfilippo Foundation is a non prof...
-
Differences in Gene Expression Patterns, Revealed by RNA-Seq Analysis, Between Various Sanfilippo and Morquio Diseas...Mucopolysaccharidoses (MPS) are genetic ...
-
Music Therapy and Sanfilippo Syndrome: an Analysis of Psychological and Physiological Variables of Three Case Studie...Mucopolysaccharidosis type III (MPS III)...
-
Q&A Coronavirus and Sanfilippo Syndrome: Dr. Heather Lauhttps://www.youtube.com/watch?v=Dn3XZiHA...
-
Cure Sanfilippo Foundation – TwitterCure Sanfilippo Foundation is 501c3 nonp...
-
Oliver’s Tomorrow Night at Columbus Blue JacketsThe NHL’s Columbus Blue Jackets are de...